High reprint orders in medical journals and pharmaceutical industry funding: case-control study.

Adam E Handel; Sunil V Patel; Julia Pakpoor; George C Ebers; Ben Goldacre ORCID logo; Sreeram V Ramagopalan; (2012) High reprint orders in medical journals and pharmaceutical industry funding: case-control study. BMJ (Clinical research ed), 344 (jun28 ). e4212-. ISSN 0959-8138 DOI: 10.1136/bmj.e4212
Copy

OBJECTIVES: To assess the extent to which funding and study design are associated with high reprint orders. DESIGN: Case-control study. SETTING: Top articles by size of reprint orders in seven journals, 2002-09. PARTICIPANTS: Lancet, Lancet Neurology, Lancet Oncology (Lancet Group), BMJ, Gut, Heart, and Journal of Neurology, Neurosurgery & Psychiatry (BMJ Group) matched to contemporaneous articles not in the list of high reprint orders. MAIN OUTCOME MEASURES: Funding and design of randomised controlled trials or other study designs. RESULTS: Median reprint orders for the seven journals ranged from 3000 to 126,350. Papers with high reprint orders were more likely to be funded by the pharmaceutical industry than were control papers (industry funding versus other or none: odds ratio 8.64, 95% confidence interval 5.09 to 14.68, and mixed funding versus other or none: 3.72, 2.43 to 5.70). CONCLUSIONS: Funding by the pharmaceutical industry is associated with high numbers of reprint orders.


picture_as_pdf
bmj.e4212.pdf
subject
Published Version
Available under Creative Commons: NC 3.0

View Download

Atom BibTeX OpenURL ContextObject in Span Multiline CSV OpenURL ContextObject Dublin Core Dublin Core MPEG-21 DIDL EndNote HTML Citation JSON MARC (ASCII) MARC (ISO 2709) METS MODS RDF+N3 RDF+N-Triples RDF+XML RIOXX2 XML Reference Manager Refer Simple Metadata ASCII Citation EP3 XML
Export

Downloads